Esther Lim

Dr. Lim is an early career postdoctoral fellow in the Precision Cancer Therapy (PCT) group at Macquarie University, and she is currently investigating the transcriptomic and proteomic profiles of melanoma patients treated with selective kinase inhibitors and immunotherapy. Her overarching research goal is to delineate mechanisms of immune responses and translate these findings to clinical applications, particularly in improving immunotherapy efficacy.

Dr. Lim has had over 7 years cancer research experience with a focus on cancer cell biology and tumour immunology. She was previously appointed as a postdoctoral researcher at the University of Oxford (from 2011-2015), and her past studies defined pro-metastatic activity of immune cells in sustaining liver metastasis of colorectal cancer. These findings provided valuable insights into the role of the host immune system in cancer progression and were published in Hepatology (2011 and 2013) and Oncogene (2016).

Dr. Lim graduated from the University of New South Wales with a PhD degree in Pathology, and her postgraduate research elucidated how oxidative modifications of inflammatory proteins regulate immune responses, and were published in the Journal of Immunology (2008) and Journal of Biological Chemistry (2010). Prior to her PhD, Dr. Lim undertook an Honours project in her final undergraduate year, on the production and characterization of monoclonal antibodies against the chloride intracellular channel 1 (CLIC1) protein, and was awarded first class honours. In the interim of commencing her PhD degree, she worked as a research assistant in close collaboration with industrial research partners and was involved in the production of specific monoclonal antibodies under cGMP conditions for use in Phase I clinical trials.